Welcome to our dedicated page for Sangamo Therapeutics SEC filings (Ticker: SGMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sangamo Therapeutics filings document regulatory, clinical, financial and corporate-status disclosures for a genomic medicine company developing gene therapy and genome-engineering technologies. Recent 8-K reports cover operating and financial results, clinical data from the STAAR study of isaralgagene civaparvovec, or ST-920, regulatory-pathway disclosures for Fabry disease, and material-event updates tied to the company's neurology pipeline.
The filing record also includes Nasdaq listing-compliance and delisting notices, SGMO common-stock registration information, finance leadership and officer-transition disclosures, and capital-structure information. These documents formalize the company's reported results, governance changes, securities status and clinical-regulatory events under SEC reporting rules.
Sangamo Therapeutics executive Gregory D. Davis, Head of Research & Technology, had 1,630 shares of Common Stock surrendered to the company on May 25, 2026 for mandatory tax withholding tied to a restricted stock unit (RSU) vesting. The withholding used the issuer’s closing stock price of $0.1743 per share and is classified as a disposition to the issuer for reporting purposes, not an open-market trade. After this tax-withholding transaction, Davis directly holds 113,654 shares. The footnotes state this includes 3,031 shares from the May 25, 2026 vesting installment of a February 25, 2025 RSU grant, with an additional 32,633 RSU shares scheduled to vest in seven equal quarterly installments, subject to continued service under the 2018 equity incentive plan.
Sangamo Therapeutics’ Principal Accounting Officer, Nikunj Jain, reported a routine tax-withholding transaction tied to restricted stock unit (RSU) vesting. On May 25, 2026, 1,919 shares of common stock were surrendered to the company at $0.1743 per share to cover mandatory taxes.
This disposition was required under the company’s 2018 Equity Incentive Plan and was not an open-market trade. After this withholding, Jain directly holds 235,292 shares. The RSU grant that partially vested on this date delivered 2,742 shares, with 32,633 additional shares scheduled to vest in seven equal quarterly installments, subject to continued service.
Sangamo Therapeutics senior vice president and chief development officer Nathalie Dubois-Stringfellow reported a tax-related share disposition. She surrendered 4,036 shares of common stock at a value of $0.1743 per share to cover mandatory tax withholding on a restricted stock unit (RSU) vesting that occurred on May 25, 2026.
This transaction is classified as a required tax-withholding disposition to the company, not a discretionary open-market trade. After the withholding, she directly holds 328,733 shares of common stock. The vesting relates to a February 25, 2025 RSU grant under the company’s 2018 equity incentive plan.
Sangamo Therapeutics SVP Scott B. Willoughby reported a routine tax-withholding share disposition tied to restricted stock vesting. On May 25, 2026, 4,036 shares of common stock were surrendered to the company at $0.1743 per share solely to satisfy mandatory tax withholding on vested RSUs, not as an open-market trade. After this non-discretionary transaction, he directly holds 647,370 shares. A footnote notes that 7,214 shares vested from a February 25, 2025 RSU grant on the same date, with 78,750 additional RSU shares scheduled to vest in seven equal quarterly installments, subject to continued service.
Sangamo Therapeutics CEO Sandy Macrae reported a tax-withholding disposition of 12,613 shares of Common Stock. These shares came from a restricted stock unit (RSU) grant vesting on May 25, 2026 and were surrendered to the company solely to cover mandatory taxes at $0.1743 per share.
The filing notes this is treated as a disposition to the issuer for reporting purposes but is not a discretionary open-market trade. After this transaction, Macrae holds 1,895,043 shares directly. The vesting event included 22,543 shares from a February 25, 2025 RSU grant, with 246,094 additional RSU shares scheduled to vest in seven equal quarterly installments, subject to continued service.
Sangamo Therapeutics ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 40,400,067 shares of Sangamo Therapeutics Common Stock, representing 9.75% of the class. The filing states Armistice Capital serves as investment manager for the Master Fund and exercises shared voting and dispositive power over these shares.
Sangamo Therapeutics reports a first‑quarter 2026 net loss of $30,995 thousand on revenues of $1,442 thousand, down from $6,437 thousand a year earlier, as operating expenses remained high at $33,388 thousand.
Cash and cash equivalents were $27,586 thousand as of March 31, 2026, against total liabilities of $78,920 thousand and a stockholders’ deficit of $18,955 thousand.
The company raised $23,346 thousand through an underwritten equity and warrant offering and $3,732 thousand via its at‑the‑market program but still discloses substantial doubt about its ability to continue as a going concern without significant near‑term financing or partnering transactions.
Sangamo also received a Nasdaq delisting determination due to minimum bid price noncompliance; its common stock was suspended from Nasdaq trading on May 5, 2026 and began trading on the OTCQB Venture Market, while the company appeals the delisting.
Sangamo Therapeutics reported a first quarter 2026 net loss of $31.0 million, or $0.08 per share, compared with a net loss of $30.6 million, or $0.14 per share, a year earlier. Revenue fell to $1.4 million from $6.4 million, mainly due to lower collaboration and license revenue.
GAAP operating expenses declined to $33.4 million, with non-GAAP operating expenses at $31.7 million, as the company reduced personnel and facilities costs while increasing spending on BLA readiness for its Fabry disease program. Cash and cash equivalents were $27.6 million as of March 31, 2026, which Sangamo estimates will fund operations into the third quarter of 2026.
The company advanced a rolling BLA for Fabry candidate ST-920 under an FDA Accelerated Approval pathway and continued early-stage neurology programs in chronic neuropathic pain and prion disease. Sangamo’s stock was suspended from Nasdaq for not meeting the minimum bid price and began trading on the OTCQB Venture Market on May 5, 2026, while the company appeals Nasdaq’s delisting determination.
Sangamo Therapeutics filed an amended annual report to add detailed Part III information on directors, executive compensation, ownership and governance without changing previously reported financial results. The amendment also refreshes officer certifications.
The filing outlines a 2025 executive pay program where CEO Alexander Macrae’s total compensation was about $2.6 million, including equity awards and a cash bonus earned under a plan that reached 40% of corporate goals. All 2025 bonuses and approved 2025 salary increases for named executives remain deferred until the company raises additional funding, and Macrae voluntarily waived his 2025 bonus.
Board and committee retainers, director equity grants, and extensive outstanding stock option and RSU positions are described, along with major 2025 and early 2026 equity financings that raised roughly $21.1 million and $23.1 million. As of April 20, 2026, Sangamo had 414,275,509 shares outstanding, with Armistice Capital and Yorkville each holding more than 10% of the common stock, subject to warrant-related beneficial ownership limits.
Sangamo Therapeutics has been notified by Nasdaq that its common stock will be delisted for continued failure to meet the $1.00 per share minimum bid price requirement. Nasdaq plans to suspend trading on the Nasdaq Capital Market at the open on May 5, 2026.
The company plans to request a hearing before a Nasdaq Hearings Panel, which would stay the delisting determination but not the trading suspension. Sangamo has obtained approval for its shares to be quoted on the OTCQB Venture Market and expects OTCQB trading to begin on May 5, 2026 under the symbol SGMO.